This overlap poses a unique therapeutic dilemma because methylene blue, the standard treatment for methemoglobinemia, requires nicotinamide adenine dinucleotide phosphate generated via the G6PD pathway and is, therefore, contraindicated in people with G6PD deficiency. The gene discussed is G6PD; the disease is G6PD deficiency.